UNSPSC 51453201: Oxamniquine

This classification denotes an antihelminthic agent with the molecular formula C14H21N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O977R722D, chemically known as 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol but generally known as oxamniquine, which bears US NIH Compound Identifier 4612. European Medicines Agency schedules Oxamniquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09494MIG.

UNSPSC 51453201 Oxamniquine is a Commodity-tier code nominally designating a single antiparasitic pharmaceutical product, but the recent state and local solicitations tagged under it show minimal actual purchasing of oxamniquine itself. Instead, the code appears to capture a broader range of pharmaceutical procurement — naloxone (opioid reversal agents), generic multi-source pharmaceuticals, over-the-counter products, and medical and first aid supplies — suggesting the code either functions as a catch-all for pharmaceutical and medical consumables in some jurisdictions' procurement systems, or the tagging reflects misalignment between the code's narrow product scope and how state and local buyers classify their buys. The issuing bodies span state health agencies (Texas Health and Human Services Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), municipal fire and rescue services (City of Tampa), and multi-state cooperative purchasing alliances (MMCAP), indicating pharmaceutical and medical supply procurement crosses agency types and administrative levels.

The geographic footprint of recent activity includes Texas, Minnesota (with participating Oregon), Florida, and surrounding regions. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units naloxone and 800 systems annually, response due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for the Tampa Fire Department Rescue Division ($700,000 estimated contract value, response due March 13, 2026, with a 5% bid discount for certified Small Local Business Enterprises), MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across multiple state and local facilities (proposals due March 26, 2026, with products required available by May 15, 2026 and contract effective July 1, 2026), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response due April 3, 2026). Cooperative purchasing vehicles and state health procurement offices dominate recent activity, with contract terms typically spanning one to two years and inclusive delivery or distribution through authorized wholesalers.